Review

rabbit anti human smad3 (Boster Bio)

Boster Bio is a verified supplier

Boster Bio manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

Boster Bio rabbit anti human smad3
Rabbit Anti Human Smad3, supplied by Boster Bio, used in various techniques. Bioz Stars score: 90/100, based on 15 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dpc4/Human+Smad4+Recombinant+Protein/pmc06923747-133-3-8
Average 90 stars, based on 15 article reviews

rabbit anti human smad3 - by Bioz Stars, 2026-10

90/100 stars

Images

Blocking Assay:

Article Title: Identification of an activation-related protein in B cells in the ABO incompatible condition
Article Snippet: In this experiment, rabbit anti-human Smad3 (dilution 1:200; BosterBio; cat. no. BA4559) and mouse anti-human Smad4 (dilution 1:200; BosterBio; cat. no. BM1601) were used as the primary antibodies, and goat anti-rabbit IgG-HRP (dilution 1:5,000; Cell Signaling Technology; cat. no. 7074S) and goat anti-mouse IgG-HRP (dilution 1:5,000; Sigma-Aldrich; Merck KGaA; cat. no. AP308P) were used as the secondary antibodies. .. After 1 μl mouse anti-human HP (dilution 1:1,000; Abcam; cat. no. ab13429), rabbit anti-human HP (dilution 1:200), or mouse anti-human Smad4 (dilution 1:200; BosterBio) was applied to PVDF membranes, the membranes were blocked with blocking buffer at room temperature for 1 h. Following 3 washes with TBS for 5 min each, the cell protein extraction of the HK2+PBMC group (dilution 1:50) was added to the membranes and incubated at room temperature for 1 h and then rinsed 3 times with TBS for 5 min each. ..

Article Title: Gut microbiota dysbiosis impairs TGF-β/Smad4 signaling to drive postoperative metastasis in colorectal cancer
Article Snippet: .. After 2 h blocking with 5% BSA, membranes were probed overnight at 4 °C with primary antibodies against TGF-β (1:1,000; Boster, China) and Smad4 (1:1,000; Boster, China). .. Subsequently, the membrane was incubated with anti-rabbit IgG antibodies (1:100,000, Abcam, UK) for 2 h at room temperature.

Protein Extraction:

Incubation:

Western Blot:

Article Title: Integrated serum pharmacochemistry, network pharmacology and transcriptomics reveals the mechanism of Periploca forrestii on rheumatoid arthritis bone erosion.
Article Snippet: Ethnopharmacological relevance: Periploca forrestii Schltr. (PF), classified among the “Ten Major Miao Medicinal Herbs” of Guizhou, China, has been traditionally used in Miao medicine to treat fractures and rheumatoid arthritis (RA), in accordance with the principle of “using vines to alleviate obstruction-related pain.” However, the mechanism underlying its bone-protective effects, particularly regarding bone metabolism regulation in RA, remains incompletely elucidated.. Aim of the study: To investigate the potential pharmacodynamic material basis and mechanisms of PF against RAassociated bone erosion by integrating serum pharmacochemistry, network pharmacology, and transcriptomics, with in vivo experimental validation, thereby providing scientific evidence for its traditional application.. Materials and methods: Chemical constituents of PF and its plasma-absorbed components were characterized using UPLC-Q-TOF-MS and GNPS molecular networking, while potential targets and pathways were predicted through network pharmacology.

Image Search Results

Tumors with loss of SMAD4 display reduced lymphocyte infiltration independent of neoadjuvant chemotherapy status. (A) Excisional biopsies from 36 PDAC patients were sectioned and stained either with H&E or via immunohistochemistry for SMAD4, the pan-leukocyte antigen CD45, or T-cell marker CD3 and representative images shown for each from either chemotherapy naïve patients (N=18) or patients who had received neoadjuvant Gemcitabine-based chemotherapy (N=18). (B, C) The percent of patients from either the chemo-naïve or neoadjuvant Gemcitabine group that was either SMAD4-expressing (SMAD4+) or SMAD4-non-expressing (SMAD4-). (D, E) The number of CD45+ or CD3+ cells per 40X field was quantified by three blinded investigators, related to chemotherapy status, and displayed as an individual value plot. Using these values, the number of CD45 positive cells was next related to SMAD4 status in either (F) the chemo naïve group or (G) the neoadjuvant Gemcitabine group and displayed as an individual value plot. (H, I) The number of CD3+ T-cells were quantified as described and related to SMAD4 status in either the chemo-naïve group or the neoadjuvant Gemcitabine group and displayed as an individual value plot. (*p < 0.05).

Journal: Frontiers in Oncology

Article Title: Loss of SMAD4 Is Associated With Poor Tumor Immunogenicity and Reduced PD-L1 Expression in Pancreatic Cancer

doi: 10.3389/fonc.2022.806963

Figure Lengend Snippet: Tumors with loss of SMAD4 display reduced lymphocyte infiltration independent of neoadjuvant chemotherapy status. (A) Excisional biopsies from 36 PDAC patients were sectioned and stained either with H&E or via immunohistochemistry for SMAD4, the pan-leukocyte antigen CD45, or T-cell marker CD3 and representative images shown for each from either chemotherapy naïve patients (N=18) or patients who had received neoadjuvant Gemcitabine-based chemotherapy (N=18). (B, C) The percent of patients from either the chemo-naïve or neoadjuvant Gemcitabine group that was either SMAD4-expressing (SMAD4+) or SMAD4-non-expressing (SMAD4-). (D, E) The number of CD45+ or CD3+ cells per 40X field was quantified by three blinded investigators, related to chemotherapy status, and displayed as an individual value plot. Using these values, the number of CD45 positive cells was next related to SMAD4 status in either (F) the chemo naïve group or (G) the neoadjuvant Gemcitabine group and displayed as an individual value plot. (H, I) The number of CD3+ T-cells were quantified as described and related to SMAD4 status in either the chemo-naïve group or the neoadjuvant Gemcitabine group and displayed as an individual value plot. (*p < 0.05).

Article Snippet: The pRK DPC4 Flag (SMAD4 WT ) plasmid has been previously reported , and was purchased from Addgene (Watertown, MA, plasmid #12627; http://n2t.net/addgene:12627 ; RRID: Addgene_12627), expanded in bacterial culture, purified using the Qiagen miniprep kit (Qiagen, Hilden, Germany), and used at a final concentration of 4μg per each well of a 6-well plate.

Techniques: Staining, Immunohistochemistry, Marker, Expressing

SMAD4 expression and increased T-cell infiltration predict for improved overall survival in PDAC patients. Kaplan-Meier curve indicating months of overall survival following surgical resection for a cohort of 36 patients arranged by: (A) SMAD4 status determined by immunohistochemistry, (B) SMAD4 status for only the patients that received no neoadjuvant therapy, (C) SMAD4 status for only the patients that received neoadjuvant Gemcitabine-based chemotherapy, (D) Patients above or below the median value for CD3+ T-cells per high power field, (E) T-cells status for only the patients that received no neoadjuvant therapy, (F) T-cells status for only the patients that received neoadjuvant Gemcitabine-based chemotherapy.

Journal: Frontiers in Oncology

Article Title: Loss of SMAD4 Is Associated With Poor Tumor Immunogenicity and Reduced PD-L1 Expression in Pancreatic Cancer

doi: 10.3389/fonc.2022.806963

Figure Lengend Snippet: SMAD4 expression and increased T-cell infiltration predict for improved overall survival in PDAC patients. Kaplan-Meier curve indicating months of overall survival following surgical resection for a cohort of 36 patients arranged by: (A) SMAD4 status determined by immunohistochemistry, (B) SMAD4 status for only the patients that received no neoadjuvant therapy, (C) SMAD4 status for only the patients that received neoadjuvant Gemcitabine-based chemotherapy, (D) Patients above or below the median value for CD3+ T-cells per high power field, (E) T-cells status for only the patients that received no neoadjuvant therapy, (F) T-cells status for only the patients that received neoadjuvant Gemcitabine-based chemotherapy.

Techniques: Expressing, Immunohistochemistry

Loss of SMAD4 impairs CCL, CXCL, and IL-family cytokine synthesis in PDAC cells. An equal number of PANC-1 cells were seeded into 6-well plates and incubated either with a control siRNA (siControl) or siRNA against SMAD4 (siSMAD4). After 24 hours, cells were treated with either a saline vehicle or 10ng/mL of recombinant TGFβ1. Following another 24 hours, cells were incubated with a protein transport inhibitor for one hour, lysed, and 200μg of total cell lysate was evaluated by a high throughput proteome profiler array (ARY022B). Pixel density was evaluated using ImageJ, and samples normalized to the mean intensity of the reference spots for each blot minus the background density. Values are presented as fold change for (A) CCL family cytokines/chemokines, (B) CXCL and IL family cytokines/chemokines, (C) additional immunomodulatory proteins. (*p < 0.05).

Journal: Frontiers in Oncology

Article Title: Loss of SMAD4 Is Associated With Poor Tumor Immunogenicity and Reduced PD-L1 Expression in Pancreatic Cancer

doi: 10.3389/fonc.2022.806963

Figure Lengend Snippet: Loss of SMAD4 impairs CCL, CXCL, and IL-family cytokine synthesis in PDAC cells. An equal number of PANC-1 cells were seeded into 6-well plates and incubated either with a control siRNA (siControl) or siRNA against SMAD4 (siSMAD4). After 24 hours, cells were treated with either a saline vehicle or 10ng/mL of recombinant TGFβ1. Following another 24 hours, cells were incubated with a protein transport inhibitor for one hour, lysed, and 200μg of total cell lysate was evaluated by a high throughput proteome profiler array (ARY022B). Pixel density was evaluated using ImageJ, and samples normalized to the mean intensity of the reference spots for each blot minus the background density. Values are presented as fold change for (A) CCL family cytokines/chemokines, (B) CXCL and IL family cytokines/chemokines, (C) additional immunomodulatory proteins. (*p < 0.05).

Techniques: Incubation, Control, Saline, Recombinant, High Throughput Screening Assay

$JURKAT T-cells remain refractory from full activation when grown in conditioned media from SMAD4-deficient tumor cells. (A) PANC-1 tumor cells were incubated with either a control siRNA (siControl) or siRNA against SMAD4 (siSMAD4) and stimulated with 10ng/mL of recombinant TGFβ1 after 24 hours. Four hours after treatment, media was changed to serum-free DMEM and collected after another 24 hours. This media was supplemented with 10% FBS and 2μl/mL ImmunoCult Human CD3/CD28 T Cell Activator and administered to 1 million serum-starved JURKAT T-cells. After 24 hours, JURKAT cells were collected, incubated with a protein transport inhibitor for one hour, and analyzed for T-cell activation by flow cytometry for the activation markers CD69, IFNγ, or CD69 and IFNγ. (B) The modal expression of CD69 and IFNγ is displayed as a histogram plot. (C) Using the described gating, the relative percent of CD69+ and IFNγ+ events are plotted, as are the absolute number of each per 10,000 events (*p < 0.05). (D) MIA PaCa-2 tumor cells were incubated with either a siControl or siSMAD4, treated similarly, and media collected as described. This media was supplemented with 10% FBS and 2μl/mL ImmunoCult Human CD3/CD28 T Cell Activator, and administered to 1 million serum-starved JURKAT T-cells, which were analyzed by flow cytometry as described previously. (E) The modal expression of CD69 and IFNγ is displayed as a histogram plot. (F) Using the described gating, the relative percent of CD69+ and IFNγ+ events are plotted, as are the absolute number of each per 10,000 events. (*p < 0.05).$

Journal: Frontiers in Oncology

Article Title: Loss of SMAD4 Is Associated With Poor Tumor Immunogenicity and Reduced PD-L1 Expression in Pancreatic Cancer

doi: 10.3389/fonc.2022.806963

Figure Lengend Snippet: JURKAT T-cells remain refractory from full activation when grown in conditioned media from SMAD4-deficient tumor cells. (A) PANC-1 tumor cells were incubated with either a control siRNA (siControl) or siRNA against SMAD4 (siSMAD4) and stimulated with 10ng/mL of recombinant TGFβ1 after 24 hours. Four hours after treatment, media was changed to serum-free DMEM and collected after another 24 hours. This media was supplemented with 10% FBS and 2μl/mL ImmunoCult Human CD3/CD28 T Cell Activator and administered to 1 million serum-starved JURKAT T-cells. After 24 hours, JURKAT cells were collected, incubated with a protein transport inhibitor for one hour, and analyzed for T-cell activation by flow cytometry for the activation markers CD69, IFNγ, or CD69 and IFNγ. (B) The modal expression of CD69 and IFNγ is displayed as a histogram plot. (C) Using the described gating, the relative percent of CD69+ and IFNγ+ events are plotted, as are the absolute number of each per 10,000 events (*p < 0.05). (D) MIA PaCa-2 tumor cells were incubated with either a siControl or siSMAD4, treated similarly, and media collected as described. This media was supplemented with 10% FBS and 2μl/mL ImmunoCult Human CD3/CD28 T Cell Activator, and administered to 1 million serum-starved JURKAT T-cells, which were analyzed by flow cytometry as described previously. (E) The modal expression of CD69 and IFNγ is displayed as a histogram plot. (F) Using the described gating, the relative percent of CD69+ and IFNγ+ events are plotted, as are the absolute number of each per 10,000 events. (*p < 0.05).

Techniques: Activation Assay, Incubation, Control, Recombinant, Flow Cytometry, Expressing

TGFβ/SMAD signaling downregulates PD-L1 expression in vitro , yet SMAD4-intact tumors have higher expression of PD-L1 in vivo. (A) Non-malignant HPNE cells and human PDAC cell lines PANC-1, MIA PaCa-2, CaPan-1, CaPan-2, BxPC-3, and AsPC-1 were lysed and analyzed for basal expression of SMAD4, PD-L1, and HLA-A,B,C by western blot. (B-D) PANC-1, BxPC-3, and AsPC-1 cells were incubated with either a saline vehicle or 10ng/mL of recombinant TGFβ1 and evaluated after 24 hours by western blot. (E) PANC-1 and MIA PaCa-2 cells were incubated with either a control siRNA (siControl) or siRNA against SMAD4 (siSMAD4), and after 24 hours, CD274 (PD-L1) mRNA was evaluated by qPCR. (F, G) PANC-1 and MIA PaCa-2 cells were incubated with either siControl or siSMAD4 and, after 24 hours, stimulated with 10ng/mL of recombinant TGFβ1. Cells were lysed after another 24-hour period and evaluated by western blot analysis. (H) BxPC-3 cells were transfected with a wild-type SMAD4 plasmid (SMAD4 WT ). After 24 hours, cells were stimulated with 10ng/mL of recombinant TGFβ1 and evaluated by western blot analysis after another 24 hours. (I) Using the TCGA genomic database of pancreatic cancer patients (N=186), the 149 fully sequenced tumors were separated into two groups: those with no SMAD4 alteration (SMAD4 wild-type or WT), and those with presumptive SMAD4 loss via a known inactivating mutation, mRNA downregulation, and/or copy number deletion. We then compared the mRNA expression of CD274 in each group. (J) SMAD4 mRNA expression was plotted against that of CD274 . All mRNA expression values are plotted in log scale and are displayed with the associated p and Spearmen (S) coefficient values. (K) Excisional biopsies from two cohorts of PDAC patients (N=44 and N=36, respectively) were sectioned and stained via immunohistochemistry for SMAD4 or PD-L1. (L-N) Patients were grouped as being either SMAD4-expressing (SMAD4+) or SMAD4-non-expressing (SMAD4-), and the percent of each group also positive for PD-L1 displayed as a pie chart. (*p < 0.05).

Journal: Frontiers in Oncology

Article Title: Loss of SMAD4 Is Associated With Poor Tumor Immunogenicity and Reduced PD-L1 Expression in Pancreatic Cancer

doi: 10.3389/fonc.2022.806963

Figure Lengend Snippet: TGFβ/SMAD signaling downregulates PD-L1 expression in vitro , yet SMAD4-intact tumors have higher expression of PD-L1 in vivo. (A) Non-malignant HPNE cells and human PDAC cell lines PANC-1, MIA PaCa-2, CaPan-1, CaPan-2, BxPC-3, and AsPC-1 were lysed and analyzed for basal expression of SMAD4, PD-L1, and HLA-A,B,C by western blot. (B-D) PANC-1, BxPC-3, and AsPC-1 cells were incubated with either a saline vehicle or 10ng/mL of recombinant TGFβ1 and evaluated after 24 hours by western blot. (E) PANC-1 and MIA PaCa-2 cells were incubated with either a control siRNA (siControl) or siRNA against SMAD4 (siSMAD4), and after 24 hours, CD274 (PD-L1) mRNA was evaluated by qPCR. (F, G) PANC-1 and MIA PaCa-2 cells were incubated with either siControl or siSMAD4 and, after 24 hours, stimulated with 10ng/mL of recombinant TGFβ1. Cells were lysed after another 24-hour period and evaluated by western blot analysis. (H) BxPC-3 cells were transfected with a wild-type SMAD4 plasmid (SMAD4 WT ). After 24 hours, cells were stimulated with 10ng/mL of recombinant TGFβ1 and evaluated by western blot analysis after another 24 hours. (I) Using the TCGA genomic database of pancreatic cancer patients (N=186), the 149 fully sequenced tumors were separated into two groups: those with no SMAD4 alteration (SMAD4 wild-type or WT), and those with presumptive SMAD4 loss via a known inactivating mutation, mRNA downregulation, and/or copy number deletion. We then compared the mRNA expression of CD274 in each group. (J) SMAD4 mRNA expression was plotted against that of CD274 . All mRNA expression values are plotted in log scale and are displayed with the associated p and Spearmen (S) coefficient values. (K) Excisional biopsies from two cohorts of PDAC patients (N=44 and N=36, respectively) were sectioned and stained via immunohistochemistry for SMAD4 or PD-L1. (L-N) Patients were grouped as being either SMAD4-expressing (SMAD4+) or SMAD4-non-expressing (SMAD4-), and the percent of each group also positive for PD-L1 displayed as a pie chart. (*p < 0.05).

Techniques: Expressing, In Vitro, In Vivo, Western Blot, Incubation, Saline, Recombinant, Control, Transfection, Plasmid Preparation, Mutagenesis, Staining, Immunohistochemistry

IFNγ overcomes the inhibitory effects of TGFβ/SMAD signaling on PD-L1 expression both in vivo and in vitro. (A) Excisional biopsies from 44 PDAC patients in cohort A and 36 PDAC patients in cohort B were sectioned and stained with H&E, lymphocytes quantified per 40X field, and arranged by PD-L1 status. (B-D) Using the TCGA genomic database of pancreatic cancer patients, CD274 mRNA expression was plotted against that of CD3E , CD3G , and IFNG . (E-G) Also, using the TCGA genomic database, IFNG mRNA expression was plotted against that of CD3E , CD3G , or SMAD4. ( H ) The 36 excisional PDAC specimens from cohort B were stained by immunohistochemistry for IFNγ, as well as dual-stained for either the duct marker CK19 and IFNγ, epithelial surrogate marker E-Cadherin and IFNγ, or the T-cell marker CD3 and IFNγ. The percent area positive for IFNγ was quantified as described and related to SMAD4 status. (I) The number of CD3+IFNγ+ cells were quantified per 40X field and arranged by both SMAD4 and PD-L1 status. (J) PANC-1 cells were incubated with 1ng/mL of recombinant IFNγ in the presence of increasing doses of recombinant TGFβ1, and PD-L1 expression evaluated by western blot after 24 hours. (K) PANC-1 cells were again incubated with either siControl or siSMAD4 and, after 24 hours, stimulated with 10ng/mL of recombinant TGFβ1. This experiment was also conducted in the presence of 1ng/mL recombinant IFNγ given concurrently with TGFβ1, and 24-hours after stimulation, cells were evaluated by western blot. (*p < 0.05).

Journal: Frontiers in Oncology

Article Title: Loss of SMAD4 Is Associated With Poor Tumor Immunogenicity and Reduced PD-L1 Expression in Pancreatic Cancer

doi: 10.3389/fonc.2022.806963

Figure Lengend Snippet: IFNγ overcomes the inhibitory effects of TGFβ/SMAD signaling on PD-L1 expression both in vivo and in vitro. (A) Excisional biopsies from 44 PDAC patients in cohort A and 36 PDAC patients in cohort B were sectioned and stained with H&E, lymphocytes quantified per 40X field, and arranged by PD-L1 status. (B-D) Using the TCGA genomic database of pancreatic cancer patients, CD274 mRNA expression was plotted against that of CD3E , CD3G , and IFNG . (E-G) Also, using the TCGA genomic database, IFNG mRNA expression was plotted against that of CD3E , CD3G , or SMAD4. ( H ) The 36 excisional PDAC specimens from cohort B were stained by immunohistochemistry for IFNγ, as well as dual-stained for either the duct marker CK19 and IFNγ, epithelial surrogate marker E-Cadherin and IFNγ, or the T-cell marker CD3 and IFNγ. The percent area positive for IFNγ was quantified as described and related to SMAD4 status. (I) The number of CD3+IFNγ+ cells were quantified per 40X field and arranged by both SMAD4 and PD-L1 status. (J) PANC-1 cells were incubated with 1ng/mL of recombinant IFNγ in the presence of increasing doses of recombinant TGFβ1, and PD-L1 expression evaluated by western blot after 24 hours. (K) PANC-1 cells were again incubated with either siControl or siSMAD4 and, after 24 hours, stimulated with 10ng/mL of recombinant TGFβ1. This experiment was also conducted in the presence of 1ng/mL recombinant IFNγ given concurrently with TGFβ1, and 24-hours after stimulation, cells were evaluated by western blot. (*p < 0.05).

Techniques: Expressing, In Vivo, In Vitro, Staining, Immunohistochemistry, Marker, Incubation, Recombinant, Western Blot

Journal: Frontiers in Oncology

Article Title: Large-Section Histopathology Can Better Indicate the Immune Microenvironment and Predict the Prognosis of Pancreatic Ductal Adenocarcinoma Than Small-Section Histopathology

doi: 10.3389/fonc.2021.694933

Figure Lengend Snippet: Main reagents and instruments.

Article Snippet: IHC: mouse anti-DPC4 (monoclonal, B-8) , ZSGB-BIO , ZM-0097.

Techniques: Polymer, Imaging

Expression profiles of 5 immune cell markers and PDL1, CDX2, and DPC4 in PDAC specimens. (A) Patterns of positive expression of CD4, CD8, CD15, CD20, and CD56 in LSH and SSH (scale bar=50 μm) and colocalization of 5 types of immune cells present in the TME of pancreatic head ductal adenocarcinoma in a 50-year-old man based on multiple immunohistochemical staining. Basic information of patients corresponding to CD4, CD8, CD15, CD20, and CD56 levels (LSH vs SSH): a 72-year-old man, a 61-year-old man, and a 66-year-old woman with a tumor located in the head of pancreas and a 54-year-old woman and a 67-year-old man with a tumor located in the tail of pancreas, respectively. (B) The expression levels of five immune cell markers were significantly higher in LSH than in SSH group (*** P =0.0002, **** P <0.0001). (C) PDL1, CDX2, and DPC4 expression in PDAC. Basic information of patients corresponding to CDX2, DPC4, and PDL1 levels: a 50-year-old man with a tumor located in the head of the pancreas and a 66-year-old man and a 60-year-old man with a tumor located in the tail of the pancreas, respectively. CD4LSH and CD4SSH represent the levels of CD4 expression in LSH and SSH, respectively, and other abbreviations can be deduced by analogy. PDAC, pancreatic ductal adenocarcinoma.

Journal: Frontiers in Oncology

Article Title: Large-Section Histopathology Can Better Indicate the Immune Microenvironment and Predict the Prognosis of Pancreatic Ductal Adenocarcinoma Than Small-Section Histopathology

doi: 10.3389/fonc.2021.694933

Figure Lengend Snippet: Expression profiles of 5 immune cell markers and PDL1, CDX2, and DPC4 in PDAC specimens. (A) Patterns of positive expression of CD4, CD8, CD15, CD20, and CD56 in LSH and SSH (scale bar=50 μm) and colocalization of 5 types of immune cells present in the TME of pancreatic head ductal adenocarcinoma in a 50-year-old man based on multiple immunohistochemical staining. Basic information of patients corresponding to CD4, CD8, CD15, CD20, and CD56 levels (LSH vs SSH): a 72-year-old man, a 61-year-old man, and a 66-year-old woman with a tumor located in the head of pancreas and a 54-year-old woman and a 67-year-old man with a tumor located in the tail of pancreas, respectively. (B) The expression levels of five immune cell markers were significantly higher in LSH than in SSH group (*** P =0.0002, **** P <0.0001). (C) PDL1, CDX2, and DPC4 expression in PDAC. Basic information of patients corresponding to CDX2, DPC4, and PDL1 levels: a 50-year-old man with a tumor located in the head of the pancreas and a 66-year-old man and a 60-year-old man with a tumor located in the tail of the pancreas, respectively. CD4LSH and CD4SSH represent the levels of CD4 expression in LSH and SSH, respectively, and other abbreviations can be deduced by analogy. PDAC, pancreatic ductal adenocarcinoma.

Article Snippet: The primary antibodies used in this study included those against CD4 (SP35), CD8 (SP16), CD15 (MMA), CD20 (L26), and CD56 (123C3.D5), all purchased from Fuzhou Maxin Biotechnologies Development Co., Ltd., and those against PDL1 (SP142), CDX2 (EP25), and DPC4 (B-8), all purchased from Beijing Zhongshan Jinqiao Biotechnology Co., Ltd.

Techniques: Expressing, Immunohistochemical staining, Staining

Relationship between CD4, CD8, CD15, CD20, CD56, PDL1, CDX2, and DPC4 expression and clinicopathologic features of PDAC.

Journal: Frontiers in Oncology

Article Title: Large-Section Histopathology Can Better Indicate the Immune Microenvironment and Predict the Prognosis of Pancreatic Ductal Adenocarcinoma Than Small-Section Histopathology

doi: 10.3389/fonc.2021.694933

Figure Lengend Snippet: Relationship between CD4, CD8, CD15, CD20, CD56, PDL1, CDX2, and DPC4 expression and clinicopathologic features of PDAC.

Techniques: Expressing

Univariate and multivariate analyses of the clinicopathological parameters and prognosis of PDAC patients in this study cohort.

Journal: Frontiers in Oncology

Article Title: Large-Section Histopathology Can Better Indicate the Immune Microenvironment and Predict the Prognosis of Pancreatic Ductal Adenocarcinoma Than Small-Section Histopathology

doi: 10.3389/fonc.2021.694933

Figure Lengend Snippet: Univariate and multivariate analyses of the clinicopathological parameters and prognosis of PDAC patients in this study cohort.

Techniques: Expressing

Nomogram predicting the survival rates of PDAC patients at 6 months, 1 year, and 2 years after surgery (A) and a survival curve of individual risk stratification based on the nomogram (B) . pTNM-pathology tumor-node-metastasis; CD4LSH, CD4 expression in large-section histopathology; CD8LSH - CD8 expression in large-section histopathology; CD15LSH, CD15 expression in large-section histopathology; PDL1, programmed cell death-ligand 1; CDX2, caudal-type homeobox 2; DPC4, deleted in pancreatic carcinoma 4.

Journal: Frontiers in Oncology

Article Title: Large-Section Histopathology Can Better Indicate the Immune Microenvironment and Predict the Prognosis of Pancreatic Ductal Adenocarcinoma Than Small-Section Histopathology

doi: 10.3389/fonc.2021.694933

Figure Lengend Snippet: Nomogram predicting the survival rates of PDAC patients at 6 months, 1 year, and 2 years after surgery (A) and a survival curve of individual risk stratification based on the nomogram (B) . pTNM-pathology tumor-node-metastasis; CD4LSH, CD4 expression in large-section histopathology; CD8LSH - CD8 expression in large-section histopathology; CD15LSH, CD15 expression in large-section histopathology; PDL1, programmed cell death-ligand 1; CDX2, caudal-type homeobox 2; DPC4, deleted in pancreatic carcinoma 4.

Techniques: Expressing, Histopathology

Review

rabbit anti human smad3 (Boster Bio)

Structured Review

Images

Related Articles

Blocking Assay:

Protein Extraction:

Incubation:

Western Blot:

Similar Products

Image Search Results